IL-22-producing Th22 cells play a protective role in CVB3-induced chronic myocarditis and dilated cardiomyopathy by inhibiting myocardial fibrosis

Virology Journal

Volumn 11, Issue 1, 2014, Pages

  Guo, Yujie ^a   Wu, Weifeng ^a   Cen, Zhihong ^a   Li, Xiaomo ^a   Kong, Qing ^a   Zhou, Qiuxi ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Chronic myocarditis; Dilated cardiomyopathy; IL 22; Myocardial fibrosis; Th22 cells

Indexed keywords

COLLAGEN; COLLAGEN TYPE A1; COLLAGEN TYPE III A1; GELATINASE B; IMMUNOGLOBULIN G; INTERLEUKIN 22; INTERLEUKIN 22 NEUTRALIZING ANTIBODY; INTERLEUKIN 22 RECEPTOR; INTERLEUKIN RECEPTOR; NEUTRALIZING ANTIBODY; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG; INTERLEUKIN DERIVATIVE; INTERLEUKIN-22; INTERLEUKIN-22 RECEPTOR;

ACUTE VIRAL MYOCARDITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC MYOCARDITIS; COLLAGEN VOLUME FRACTION; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; COXSACKIEVIRUS B3; DISEASE EXACERBATION; DISEASE SEVERITY; FRACTIONATION; HEART MUSCLE FIBROSIS; MALE; MOUSE; MYOCARDITIS; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SURVIVAL RATE; TH22 CELL; UPREGULATION; VIRUS MYOCARDITIS; ANIMAL; BAGG ALBINO MOUSE; COXSACKIE VIRUS INFECTION; DISEASE COURSE; DISEASE MODEL; ENTEROVIRUS B; FIBROSIS; GENETICS; HELPER CELL; HUMAN; IMMUNOLOGY; PATHOLOGY; PHYSIOLOGY; VIROLOGY;

COXSACKIEVIRUS; MUS;

ANIMALS; CARDIOMYOPATHY, DILATED; COXSACKIEVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENTEROVIRUS B, HUMAN; FIBROSIS; HUMANS; INTERLEUKINS; MALE; MICE; MICE, INBRED BALB C; MYOCARDITIS; RECEPTORS, INTERLEUKIN; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84936865671     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/s12985-014-0230-z     Document Type: Article

References (33)

1. Poller W, Schultheiss HP, Kuhl U: Viruses and other environmental factors as possible sources of phenotypic heterogeneity in familial dilated cardiomyopathy. J Am Coll Cardiol 2006, 47(3):689-690. author reply 690.
2. Kawai C: From myocarditis to cardiomyopathy: Mechanisms of inflammation and cell death: learning from the past for the future. Circulation 1999, 99(8):1091-1100.
3. Kania G, Blyszczuk P, Eriksson U: Mechanisms of cardiac fibrosis in inflammatory heart disease. Trends Cardiovasc Med 2009, 19(8):247-252.
4. Chen P, Xie Y, Shen E, Li GG, Yu Y, Zhang CB, Yang Y, Zou Y, Ge J, Chen R, Chen H: Astragaloside IV attenuates myocardial fibrosis by inhibiting TGF-beta1 signaling in coxsackievirus B3-induced cardiomyopathy. Eur J Pharmacol 2011, 658(2-3):168-174.
5. Fairweather D, Frisancho-Kiss S, Yusung SA, Barrett MA, Davis SE, Gatewood SJ, Njoku DB, Rose NR: Interferon-gamma protects against chronic viral myocarditis by reducing mast cell degranulation, fibrosis, and the profibrotic cytokines transforming growth factor-beta 1, interleukin-1 beta, and interleukin-4 in the heart. Am J Pathol 2004, 165(6):1883-1894.
6. Baldeviano GC, Barin JG, Talor MV, Srinivasan S, Bedja D, Zheng D, Gabrielson K, Iwakura Y, Rose NR, Cihakova D: Interleukin-17A is dispensable for myocarditis but essential for the progression to dilated cardiomyopathy. Circ Res 2010, 106(10):1646-1655.
7. Xue Y, Wu W, Gao M, Liu Y, Kong Q: Effect of interleukin-17A on myocardial fibrosis in mice with coxsackie-virus B3 viral myocarditis. South Chin J Cardiovasc Dis 2013, 19(3):346-351. 359.
8. Pan X, Wu W, Lai W, Xue Y, Kong Q: Influence of interleukin-17A on the pathogenesis of myocardial fibrosis by inducing transforming growth factor β1 in mice with viral myocarditis. South Chin J Cardiovasc Dis 2014, 20(2):233-237.
9. Duhen T, Geiger R, Jarrossay D, Lanzavecchia A, Sallusto F: Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol 2009, 10(8):857-863.
10. Trifari S, Kaplan CD, Tran EH, Crellin NK, Spits H: Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol 2009, 10(8):864-871.
11. Wolk K, Witte E, Witte K, Warszawska K, Sabat R: Biology of interleukin-22. Semin Immunopathol 2010, 32(1):17-31.
12. Kong Q, Wu W, Yang F, Liu Y, Xue Y, Gao M, Lai W, Pan X, Yan Y, Pang Y, Deng Y: Increased expressions of IL-22 and Th22 cells in the coxsackievirus B3-Induced mice acute viral myocarditis. Virol J 2012, 9:232.
13. Weber KT, Brilla CG, Janicki JS: Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res 1993, 27(3):341-348.
14. Cheung C, Marchant D, Walker EK, Luo Z, Zhang J, Yanagawa B, Rahmani M, Cox J, Overall C, Senior RM, Luo H, McManus BM: Ablation of matrix metalloproteinase-9 increases severity of viral myocarditis in mice. Circulation 2008, 117(12):1574-1582.
15. Renckens R, Roelofs JJ, Florquin S, de Vos AF, Lijnen HR, Van't Veer C, van der Poll T: Matrix metalloproteinase-9 deficiency impairs host defense against abdominal sepsis. J Immunol 2006, 176(6):3735-3741.
16. Matsumori A, Nunokawa Y, Yamaki A, Yamamoto K, Hwang MW, Miyamoto T, Hara M, Nishio R, Kitaura-Inenaga K, Ono K: Suppression of cytokines and nitric oxide production, and protection against lethal endotoxemia and viral myocarditis by a new NF-kappaB inhibitor. Eur J Heart Fail 2004, 6(2):137-144.
17. Heymans S, Pauschinger M, De Palma A, Kallwellis-Opara A, Rutschow S, Swinnen M, Vanhoutte D, Gao F, Torpai R, Baker AH, Padalko E, Neyts J, Schultheiss HP, Van de Werf F, Carmeliet P, Pinto YM: Inhibition of urokinase-type plasminogen activator or matrix metalloproteinases prevents cardiac injury and dysfunction during viral myocarditis. Circulation 2006, 114(6):565-573.
18. Loftus IM, Naylor AR, Bell PR, Thompson MM: Matrix metalloproteinases and atherosclerotic plaque instability. Br J Surg 2002, 89(6):680-694.
19. Zhao L, Ma H, Jiang Z, Jiang Y, Ma N: Immunoregulation therapy changes the frequency of interleukin (IL)-22+ CD4+ T cells in systemic lupus erythematosus patients. Clin Exp Immunol 2014, 177(1):212-218.
20. Chen J, Feng J, Chen X, Xu H, Zhou Z, Shen X, Bao Z, Liu W, Shen Z: Immunoexpression of interleukin-22 and interleukin-23 in oral and cutaneous lichen planus lesions: a preliminary study. Mediators Inflamm 2013, 2013:801974.
21. Xu W, Li R, Dai Y, Wu A, Wang H, Cheng C, Qiu W, Lu Z, Zhong X, Shu Y, Kermode AG, Hu X: IL-22 secreting CD4+ T cells in the patients with neuromyelitis optica and multiple sclerosis. J Neuroimmunol 2013, 261(1-2):87-91.
22. Benham H, Norris P, Goodall J, Wechalekar MD, FitzGerald O, Szentpetery A, Smith M, Thomas R, Gaston H: Th17 and Th22 cells in psoriatic arthritis and psoriasis. Arthritis Res Ther 2013, 15(5):R136.
23. Michalak-Stoma A, Bartosinska J, Kowal M, Juszkiewicz-Borowiec M, Gerkowicz A, Chodorowska G: Serum levels of selected Th17 and Th22 cytokines in psoriatic patients. Dis Markers 2013, 35(6):625-631.
24. Peng Z, Tian J, Cui X, Xian W, Sun H, Li E, Geng L, Zhang L, Zhao P: Increased number of Th22 cells and correlation with Th17 cells in peripheral blood of patients with IgA nephropathy. Hum Immunol 2013, 74(12):1586-1591.
25. Kim CJ, Nazli A, Rojas OL, Chege D, Alidina Z, Huibner S, Mujib S, Benko E, Kovacs C, Shin LY, Grin A, Kandel G, Loutfy M, Ostrowski M, Gommerman JL, Kaushic C, Kaul R: A role for mucosal IL-22 production and Th22 cells in HIV-associated mucosal immunopathogenesis. Mucosal Immunol 2012, 5(6):670-680.
26. Radaeva S, Sun R, Pan HN, Hong F, Gao B: Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology 2004, 39(5):1332-1342.
27. Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ, Karow M, Flavell RA: Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity 2007, 27(4):647-659.
28. Xu X, Zheng S, Yang F, Shi Y, Gu Y, Chen H, Zhang M, Yang T: Increased Th22 cells are independently associated with Th17 cells in type 1 diabetes. Endocrine 2014, 46(1):90-98.
29. Zhao R, Tang D, Yi S, Li W, Wu C, Lu Y, Hou X, Song J, Lin P, Chen L, Sun L: Elevated peripheral frequencies of Th22 cells: a novel potent participant in obesity and type 2 diabetes. PLoS One 2014, 9(1):e85770.
30. Lin YZ, Wu BW, Lu ZD, Huang Y, Shi Y, Liu H, Liu L, Zeng QT, Wang X, Ji QW: Circulating Th22 and Th9 levels in patients with acute coronary syndrome. Mediators Inflamm 2013, 2013:635672.
31. Kong Q, Li X, Wu W, Yang F, Liu Y, Lai W, Pan X, Gao M, Xue Y: Increased circulating Thelper 22 cells in patients with dilated cardiomyopathy. Mol Med Rep 2014, 10(1):359-364.
32. Kong Q, Xue Y, Wu W, Yang F, Liu Y, Gao M, Lai W, Pan X: IL-22 exacerbates the severity of CVB3-induced acute viral myocarditis in IL-17A-deficient mice. Mol Med Rep 2013, 7(4):1329-1335.
33. Eyerich S, Eyerich K, Pennino D, Carbone T, Nasorri F, Pallotta S, Cianfarani F, Odorisio T, Traidl-Hoffmann C, Behrendt H, Durham SR, Schmidt-Weber CB, Cavani A: Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest 2009, 119(12):3573-3585.